SUBSEQUENT EVENTS	3 Months Ended
Mar. 31, 2012
Notes to Financial Statements
Note 12 - SUBSEQUENT EVENTS	The Company evaluated events occurring subsequent to March 31, 2012, identifying those that are required to be disclosed as follows: On April 9, 2012, the Board of Directors of FluoroPharma Medical, Inc. (the “Company”) decided to eliminate Dr. Elmaleh’s status with the Company as an executive officer, but intends to retain his services as a consultant to the Company. Dr. Elmaleh will also continue to serve as a director of the Company and as Chairman of the Board.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

No definition available.

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration